Trials / Recruiting
RecruitingNCT07021209
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT719 Injection | GT719 Injection |
Timeline
- Start date
- 2025-01-14
- Primary completion
- 2028-01-13
- Completion
- 2028-01-13
- First posted
- 2025-06-13
- Last updated
- 2025-09-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07021209. Inclusion in this directory is not an endorsement.